Cart summary

You have no items in your shopping cart.

Dalcetrapib

SKU: orb1223190

Description

Dalcetrapib, aslo known as JTT-705, is a CETP inhibitor. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health. Development of this drug was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.(In Vitro):Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.(In Vivo):Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol.

Images & Validation

Key Properties

CAS Number211513-37-0
MW389.59
Purity>98% (HPLC)
FormulaC23H35NO2S
SMILESc1(ccccc1NC(=O)C1(CC(CC)CC)CCCCC1)SC(=O)C(C)C
TargetFGFR
SolubilityDMSO : ≥ 50 mg/mL. 128.34 mM; H2O : < 0.1 mg/mL

Bioactivity

In Vivo
Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o. ; once a day for 3 days) increases plasma HDL cholesterol in rabbits. Dalcetrapib (100 mg/kg; i. g. ; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol. Animal model: Male JW rabbits. Dosage: 30 or 100 mg/kg. Administration: Oral administration, once a day for 3 days. Result: Increased plasma HDL cholesterol by 27% and 54% at 30 mg/kg and 100 mg/kg, respectively.
In Vitro
Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation. Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

JTT-705 | JTT705 | JTT 705 | RO-4607381

Similar Products

  • Dalcetrapib [orb1301120]

    >99.99% (May vary between batches)

    211513-37-0

    389.59

    C23H35NO2S

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 2 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Dalcetrapib (orb1223190)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 80.00
5 mg
$ 110.00
10 mg
$ 130.00
25 mg
$ 210.00
50 mg
$ 300.00
100 mg
$ 500.00